Sr. Manager of External Communications
November 16, 2017
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the DISCOVERY Teal HRP kit1, the newest addition to the comprehensive collection of modular-based detection kits to identify and profile biomarkers and cell populations in tissue-based research.
DISCOVERY Teal HRP (horseradish peroxidase) kit can be used in combination with other detection kits, expanding the multiplexing capability of both immunohistochemistry (IHC) and in situ hybridization (ISH) by providing a distinct color that contrasts with other chromogens. DISCOVERY Teal HRP complements chromogens including DISCOVERY Yellow, DISCOVERY Purple and DISCOVERY Red, providing a variety of chromogens to choose from for multiplexing up to six biomarkers simultaneously.
The innovative DISCOVERY Teal HRP is translucent and can form a third color when overlapping with another chromogen, a feature that is important in research. This unique property enables researchers to analyze the co-localization of multiple biomarkers through the spatial overlapping of two signals in the context of tissue.
Roche’s DISCOVERY Teal HRP kit is supplied2 in ready-to-use dispensers and provides a stable staining signal during alcohol dehydration. It can be fully automated on the DISCOVERY ULTRA system.3
About DISCOVERY products
The DISCOVERY product line is the research use only (RUO) portfolio of instruments and reagents developed by Roche Tissue Diagnostics for research in immunohistochemistry (IHC) and in situ hybridization (ISH). Included in the product line are the DISCOVERY ULTRA research instruments to fully automate single or multiplex IHC and ISH applications and a growing line of unique, ready-to-use reagents for full automation that are designed to meet the needs of the research community. DISCOVERY products are not for use in diagnostic procedures.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
VENTANA and DISCOVERY are trademarks of Roche. Other product names and trademarks are the property of their respective owners.
Sr. Manager of External Communications
Skin tissue at 63X magnification using Roche’s DISCOVERY Purple, DISCOVERY Teal HRP and DISCOVERY Yellow
Skin tissue at 20X magnification using Roche’s DISCOVERY Teal HRP